Cell line · CVCL_0258
EoL-1
Cancer cell line, Homo sapiens. Chronic eosinophilic leukemia, not otherwise specified. 30 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. EoL-1. Cell lines, record CVCL_0258. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0258
On this page
Cell line
As Cellosaurus gives it.
- Name
- EoL-1
- Accession
- CVCL_0258
- RRID
- RRID:CVCL_0258
- Synonyms
- EOL-1, EOL1, EoL-1-cell, EoL-1 cell, AML-EOL-1
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 33Y
- Category
- Cancer cell line
- Diseases
- Chronic eosinophilic leukemia, not otherwise specified (NCIt C4563); Chronic eosinophilic leukemia (ORDO Orphanet_168940)
- Derived from
- Peripheral blood (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers30
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A triple-action PROTAC for wild-type p53 cancer therapy. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Systematic Evaluation of GAPs and GEFs Identifies a Targetable Dependency for Hematopoietic Malignancies. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Transcriptionally imprinted glycomic signatures of acute myeloid leukemia. | Cell Biosci | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| HOXA9 promotes MYC-mediated leukemogenesis by maintaining gene expression for multiple anti-apoptotic pathways. | Elife | 2021 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 30
See all 30 papersRelatives3
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | ICLU-E | CVCL_E8UB | Cell lines | |
| From the same person | EoL-2 | CVCL_S960 | Cell lines | |
| From the same person | EoL-3 | CVCL_4069 | Cell lines |
Cell banks5
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| DSMZ | ACC-386 | DSMZ | |
| ECACC | 94042252 | ECACC | |
| RCB | RCB0641 | RCB | |
| RCB | RCB3679 | Discontinued | Cellosaurus |
| TKG | TKG 0476 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0258
GET https://conductscience.org/api/cell-lines/v1/CVCL_0258/papers?page=2